GSK

GSK

Market cap $97.8B

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?

Citi is holding back from recommending GSK PLC (LSE:GSK, NYSE:GSK) shares despite a significant clinical breakthrough in hepatitis B treatment, arguing that unanswered commercial questions mean any value from the new drug is unlikely to materialise for shareholders in the near term. The bank maintains its 'neutral' rating on GSK after trial results for the company's experimental drug bepirovirsen were published in the New England Journal of Medicine.

GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript

Drug candidate bepirovirsen helped nearly a fifth of patients in two late-stage clinical trials achieve a functional cure, the company said.

GSK said its ‌experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, raising hopes for a finite treatment course as an alternative to lifelong antiviral ​pills.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

A clutch of heavyweight dividend payments knocked almost 20 points off the FTSE 100 on Thursday, with four of the index's biggest companies trading ex-dividend. HSBC Holdings PLC (LSE:HSBA) had the largest impact, removing 5.36 points from the blue-chip index as the shares traded without entitlement to the bank's latest 10-cent quarterly payout.

GSK ​on Monday ‌said it ​had ​entered into ⁠a ​strategic collaboration ​with Hong Kong-listed ​Sino ​Biopharmaceutical to ‌accelerate ⁠the launch of ​its ​hepatitis ⁠B treatment ​bepirovirsen ​in ⁠mainland ⁠China.